140 related articles for article (PubMed ID: 2643726)
21. Immunocytochemical detection of S-phase cells in normal and neoplastic cervical epithelium by anti-BrdU monoclonal antibody.
Fukuda K; Iwasaka T; Hachisuga T; Sugimori H; Tsugitomi H; Mutoh F
Anal Quant Cytol Histol; 1990 Apr; 12(2):135-8. PubMed ID: 2350389
[TBL] [Abstract][Full Text] [Related]
22. [Application of bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody for the analysis of tumor cell kinetics by flow cytometry].
Kanno M; Takeda Y; Nakamura S
Nihon Rinsho; 1992 Oct; 50(10):2333-7. PubMed ID: 1280304
[TBL] [Abstract][Full Text] [Related]
23. S-phase cells in diseased human liver determined by an in vitro BrdU-anti-BrdU method.
Shimizu A; Tarao K; Takemiya S; Harada M; Inoue T; Ono T
Hepatology; 1988; 8(6):1535-9. PubMed ID: 2847968
[TBL] [Abstract][Full Text] [Related]
24. Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric data.
Teodori L; Trinca ML; Goehde W; Hemmer J; Salvati F; Storniello G; Mauro F
Int J Cancer; 1990 Jun; 45(6):995-1001. PubMed ID: 2161804
[TBL] [Abstract][Full Text] [Related]
25. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies.
Scrivner DL; Meyer JS; Rujanavech N; Fathman A; Scully T
J Urol; 1991 Oct; 146(4):1034-9. PubMed ID: 1895419
[TBL] [Abstract][Full Text] [Related]
26. Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia.
Peschke P; Klein V; Wolber G; Friedrich E; Hahn EW
Histol Histopathol; 1999 Apr; 14(2):461-9. PubMed ID: 10212807
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometric estimation of cell cycle parameters using a monoclonal antibody to bromodeoxyuridine.
Sasaki K; Murakami T; Ogino T; Takahashi M; Kawasaki S
Cytometry; 1986 Jul; 7(4):391-5. PubMed ID: 3089742
[TBL] [Abstract][Full Text] [Related]
28. [S-phase cells of human bladder tumors by in vivo bromodeoxyuridine labeling].
Ohyama C; Nakazumi H; Satoh M; Yoshikawa K; Hoshi S; Orikasa S; Hayashi T; Mituno S; Murakami F; Kurosu S
Nihon Hinyokika Gakkai Zasshi; 1990 Apr; 81(4):524-31. PubMed ID: 2374324
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of carcinoembryonic antigen in benign hyperplasia and adenocarcinoma of the prostate with monoclonal antibody.
Ghazizadeh M; Kagawa S; Izumi K; Maebayashi K; Takigawa H; Saiki T; Kawano A; Kurokawa K
J Urol; 1984 Mar; 131(3):501-3. PubMed ID: 6199524
[TBL] [Abstract][Full Text] [Related]
30. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.
Carroll PR; Waldman FM; Rosenau W; Cohen MB; Vapnek JM; Fong P; Narayan P; Mayall BH
J Urol; 1993 Feb; 149(2):403-7. PubMed ID: 8093910
[TBL] [Abstract][Full Text] [Related]
31. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
Nagashima T; Hoshino T
No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
33. [Flow cytometric determination of S phase fractions of colorectal carcinomas using: preliminary report anti-bromodeoxyuridine monoclonal antibody].
Kitagawa T; Sugenoya Y; Matsumoto K; Suzuki H
Nihon Geka Gakkai Zasshi; 1988 Nov; 89(11):1928. PubMed ID: 3205259
[No Abstract] [Full Text] [Related]
34. [Flow cytometric analysis of cell proliferation kinetics using the anti-BrdUrd antibody].
Sasaki K; Murakami T; Takahashi M
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2338-44. PubMed ID: 2751315
[TBL] [Abstract][Full Text] [Related]
35. Cell kinetic studies using a monoclonal antibody to bromodeoxyuridine.
Wilson GD
Methods Mol Biol; 1998; 80():255-66. PubMed ID: 9664383
[No Abstract] [Full Text] [Related]
36. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical localization of prostate carcinoma-associated antigens.
Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
[TBL] [Abstract][Full Text] [Related]
38. Determination by anti-bromodeoxyuridine monoclonal antibody of cells in S phase in the human Y79 retinoblastoma line maintained in an organ culture system: effects of butyric acid.
Nakagawa Y; Perentes E
Ophthalmic Res; 1987; 19(4):205-12. PubMed ID: 3696696
[TBL] [Abstract][Full Text] [Related]
39. Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies.
Shibui S; Hoshino T; Vanderlaan M; Gray JW
J Histochem Cytochem; 1989 Jul; 37(7):1007-11. PubMed ID: 2659659
[TBL] [Abstract][Full Text] [Related]
40. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
